Search

En un ensayo clínico de MSK se descubrió que participar en clases de terapia integral en línea podría beneficiar a los pacientes que padecen cáncer y reciben tratamiento activo, no solo porque reduce la fatiga, la ansiedad y la depresión, sino también porque disminuye las tasas de hospitalización.

… Tuesday, June 17, 2025 Mientras Jan Gura se preparaba para enfrentarse a la avalancha de tratamientos estándar para el cáncer de ovario en estadio 2, sabía que también quería terapias integrales que la ayudaran a sentirse mejor.  “No sabía cómo respondería mi cuerpo a la quimioterapia, pero siempre he

A gift from the estate of renowned fashion designer Geoffrey Beene will enable MSKCC to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center.

… Wednesday, September 27, 2006 A gift from the estate of renowned fashion designer Geoffrey Beene will enable Memorial Sloan Kettering Cancer Center (MSKCC) to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center . It will build on MSKCC’s strong existing scientific

Learn how MSK is Improving patients’ quality of life with less toxic treatments.

… Monday, June 10, 2024 Marc Scarduffa was blindsided when he learned he had stage 3 rectal cancer. Fit and strong as he celebrated his 50th birthday, he had scheduled a colonoscopy simply because he knew he had reached the recommended age to begin screening for colorectal cancer (the recommended age has

A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells.

… Thursday, January 22, 2015 Summary A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells. Stem cell therapy for Parkinson’s disease has shown great promise in animal studies and is moving closer to becoming an option for people

Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award.

… Tuesday, October 4, 2022 Today Sloan Kettering Institute’s (SKI) Alexander Gitlin, MD, PhD of Memorial Sloan Kettering Cancer Center (MSK) was recognized as a winner of the National Institutes of Health (NIH) Director’s Early Independence Award. Dr. Gitlin was chosen for his outstanding work and proposal

MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.

… Monday, February 15, 2021 Update: On August 11, 2021, the FDA approved pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for first-line treatments for patients with advanced renal cell carcinoma (RCC). Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at

Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.

… Tuesday, October 22, 2019 Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will

The genome-editing technique uncovered several genes previously not known to influence embryonic development.

… Tuesday, July 2, 2019 Summary With the help of the genome-editing tool CRISPR, developmental biologists at the Sloan Kettering Institute have uncovered a set of genes that was previously unknown to influence cell fate decisions. Life is about choices. That’s as true for cells as it is for people. Every

Meet the students who were awarded fellowships based on academic excellence for the 2020–2021 academic year.

… Thursday, September 17, 2020 Every year, the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences awards fellowships to two third-year students and six second-year students based on academic excellence. Student stipends at GSK are supported by a variety of sources, including philanthropic

The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.

… Friday, June 21, 2024 The US Food and Drug Administration has granted accelerated approval  for the targeted therapy  adagrasib (Krazati ® )  in combination with the drug  cetuximab (Erbitux ® )  for people with advanced  colorectal cancer  caused by a gene mutation called  KRAS -G12C. Adagrasib is the